Study of ATRX and p53 Mutation in Astrocytomas and Its Role in Tumor Grading
DOI:
https://doi.org/10.21276/apalm.3589Keywords:
Astrocytomas, Immunohistochemistry, ATRX, p53Abstract
Background: Astrocytomas are the most common primary brain malignancies. They come under a large group of clinically, pathologically and genetically diverse glial neoplasms designated as diffuse gliomas. The majority of IDH mutant astrocytomas also harbour ATRX and p53 mutations. The aim of the present study is to analyse ATRX and p53 mutation in astrocytomas by immunohistochemistry and its role in tumor classification and grading.
Methods: The cross-sectional study was conducted in the department of neuropathology, Madras Medical College for a period of 18 months from December 2022 to May 2024. A total of 54 cases with clinical suspicion and radiological evidence of astrocytoma were included in the study. Immunohistochemical analysis of ATRX and p53 were done and expressions were evaluated.
Results: Among 54 cases, 44.5% of them are grade 2 followed by 25.9% in grade 4, 18.5% in grade 3 and 11.1% in grade 1. Correlation with age, gender and anatomical location were done. Loss of ATRX expression was significantly associated with astrocytomas (p<0.001), p53 mutation was lost in 9.3% of cases (p=0.41).
Conclusion: ATRX is an important immunohistochemical marker in astrocytomas, the loss of which is associated with higher grades, hence this can be used as a prognostic marker in astrocytomas. P53 mutation in astrocytomas may enable tumor cell survival in setting of ATRX loss.
References
1. Sathishkumar K, Chaturvedi M, Das P. Stephen S, Mathur P. Cancer incidence estimates for 2022 & projection for 2025: Result from National Cancer Registry Programme, India. Indian J Med Res. 2022 Oct-Nov;156:598-607.
2. Dasgupta A, Gupta T, Jalali R. Indian data on central nervous tumors: A summary of published work. South Asian J Cancer. 2016:5:147-53.
3. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23:1231-51.
4. Jiao Y, Killela PJ, Reitman ZJ, Rasheed BA, Heaphy CM, de Wilde RF, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3:709-22.
5. Ebrahimi A, Skardelly M, Bonzheim 1, Ott I, Mühleisen H, Franziska E, et al. ATRX immunostaining predicts IDH and H3F3A status in gliomas. Acta Neuropathol Commun. 2016;4:60.
6. Wiestler B, Capper D, Sill M, Jones DT. Hovestadt V, Sturm D, et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol. 2014;128(4):561-71.
7. Liu N, Wang P, Song H, Kong L, Yao K, Qi X, et al. Immunostaining of IDH-1 R132H and ATRX proteins in the classification of adult glioblastomas. Int J Clin Exp Pathol. 2016;9(12):12849-54.
8. Nozaki M, Tada M, Kobayashi H, Zhang CL, Sawamura Y, Abe H, et al. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro-Oncology. 1999 1:124-37.
9. Gillet E, Alentorn A, Doukoure B, Mundwiller E, Van Thuij H, Reijneveld JC, et al. TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas. J Neurooncol. 2014;118(1):131-9.
10. Wiestler B, Capper D, Holland-Letz T, et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol. 2013;126:443-51.
11. Hewer E, Vajtai I, Dettmer MS. Berezowska S, Vassella E. Combined ATRX/IDH1 immunohistochemistry predicts genotype of Oligoastrocytomas. Histopathology. 2016 Jan;68(2):272-8.
12. Cai J, Jhu P, Zhang C, Li Q, Wang Z, Li G. Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas. Oncotarget. 2016;7(13):16384-95.
13. Purakit S, Miller C, Kumar A, Sharma V. Pathak P, et al. ATRX in Diffuse Gliomas With its Mosaic/Heterogeneous Expression in a Subset. Brain Pathol. 2017 Mar 27(2):138-45.
14. Cai J, Zhang C, Zhang W, Wang G, Yao K. ATRX, IDHI-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. Oncoscience. 2016 3:258-64.
15. Chatterjee D, Radotra BD, Kumar N, Vasishta RK, Gupta SK. IDH1, ATRX, and BRAFV600E mutation in astrocytic tumors and their significance in patient outcome in north Indian population. Surg Neurol Int. 2018;9:29-34.
16. Liu J, Zhang X, Yan X, Sun M, Fan Y, et al. Significance of TERT and ATRX mutations in glioma. Oncology Letters. 2019;17:95-102.
17. Sharma S, Mathur K, Mittal A, Mukta M, Jindal A. Study of Surrogate Immunohistochemical Markers IDHI, ATRX, BRAF V600E, and p53 Mutation in Astrocytic and Oligodendroglial Tumors. Indian J Neurosurg. 2023:12:137-46.
18. Sarkar C, Ralte AM, Sharma MC, Mehta VS. Recurrent astrocytic tumours a study of p53 immunoreactivity and malignant progression. British Journal of Neurosurgery. 2002;16(4):335-42.
19. Nayak A, Ralte AM, Sharma MC, Singh VP, Mahapatra A, et al. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. Neurology India. 2004;52(2):228-33.
20. Al-Sarraj S, Bridges LR. p53 immunoreactivity in astrocytomas and its relationship to survival. British Journal of Neurosurgery. 1995:9(2):143-50.
21. Abdel-Maqsoud RR, Ali MY. Expression of P53 and Ki-67 in Different Grades of Astrocytomas. IJMA. 2022 July;4(7):2494-02.
22. Inskip PD, Tarone RE, Hatch EE, Wilcosky TC, Selker R, et al. Laterality of Brain Tumors. Neuroepidemiology. 2003;22(2):130-8.
23. Ilgren EB, Stiller CA. Cerebellar astrocytomas. Clinical characteristics and prognostic indices. J Neurooncol. 1987;4(3):293-308.
24. Pardo FS, Hsu DW, Zeheb R, Efird JT, Okunieff PG, et al. Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage. British Journal of Cancer. 2004:91:1678-86.
25. Diaz JJ, Scoggin T, Ramos J. Characterization of ATRX polyclonal, application of immunohistochemical analysis on astrocytoma and glioblastoma. Cancer Res. 2021:81(13):458.
26. Geramizadeh B, Shirazi MH, Soltani A. A Simple Panel of IDH1 and P53 in Differential Diagnosis Between Low-Grade Astrocytoma and Reactive Gliosis. Clinical Pathology. 2021:14:1-4.
27. Shao LW, Pan Y, Qi X, Li Y, Ma X. ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients. Histol Histopathol. 2016;31:103-14.
28. Noor H. Briggs NE, Mc Donald KL, Holst J, Vittorio O. TP53 Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy. Cancers. 2021:13:5362.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Sasirega R S, K Chandramouleeswari, M. Dougul Regis
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
